Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Humoral Innate Immunity and Acute-Phase Proteins | NEJM Skip to main content NEJM Group
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician …

Complement has long been considered a key innate immune effector system that mediates
host defence and tissue homeostasis. Yet, growing evidence has illuminated a broader …

COVID‐19 is a complex disease manifesting in a broad severity spectrum and involving
distinct organs and systems. Hyperinflammation, including complement over‐activation, has …

The lung naturally resists Aspergillus fumigatus (Af) in healthy individuals, but multiple
conditions can disrupt this resistance, leading to lethal invasive infections. Core processes …

Improvements in COVID-19 treatments, especially for the critically ill, require deeper
understanding of the mechanisms driving disease pathology. The complement system is not …

Within a short few years, the number of complement inhibitors that are either approved for
therapeutic application or evaluated in late‐stage clinical trials has expanded remarkably …

With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another
class of complement targeted therapeutics have recently been approved. Moreover …

COVID-19 is a severe respiratory illness that has emerged as a devasting health problem
worldwide. The disease outcome is heterogeneous, which is most likely dependent on the …

Stroke has become the first cause of functional disability and one of the leading causes of
mortality worldwide. Therefore, it is of crucial importance to develop accurate biomarkers to …